• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

难治性原发性玻璃体内视网膜淋巴瘤累及脊髓，替拉鲁替尼治疗暂时完全缓解。

Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.

机构信息

Department of Hematology, Juntendo University Urayasu Hospital, Japan.

Department of Neurosurgery, Juntendo University Urayasu Hospital, Japan.

出版信息

Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.

DOI:10.2169/internalmedicine.9591-22
PMID:35793963
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9970806/
Abstract

Many patients with primary vitreoretinal lymphoma (PVRL) exhibit central nervous system (CNS) involvement either at the diagnosis or during follow-up. The prognosis in the patients of PVRL with relapsed or refractory CNS remains extremely poor. We herein report a patient with refractory PVRL who had recurrence in the spinal cord despite receiving high-dose methotrexate-based chemotherapy and whole-brain radiotherapy. The patient surprisingly responded to tirabrutinib temporarily. We believe that this case suggests the utility of this new target therapy.

摘要

许多原发性眼内淋巴瘤（PVRL）患者在诊断时或随访期间存在中枢神经系统（CNS）受累。复发或难治性 CNS 原发性眼内淋巴瘤患者的预后仍然极差。我们在此报告一例难治性 PVRL 患者，尽管接受了大剂量甲氨蝶呤为基础的化疗和全脑放疗，但脊髓仍复发。该患者出人意料地对替拉鲁替尼暂时有反应。我们认为该病例提示了这种新的靶向治疗的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/ad000d490a5a/1349-7235-62-0459-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/6d3d2abc6436/1349-7235-62-0459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/ae6911557cbd/1349-7235-62-0459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/db122f1e8caf/1349-7235-62-0459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/ad000d490a5a/1349-7235-62-0459-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/6d3d2abc6436/1349-7235-62-0459-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/ae6911557cbd/1349-7235-62-0459-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/db122f1e8caf/1349-7235-62-0459-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a58e/9970806/ad000d490a5a/1349-7235-62-0459-g004.jpg

相似文献

1
Refractory Primary Vitreoretinal Lymphoma Involving the Spinal Cord with a Temporary Complete Response to Tirabrutinib.难治性原发性玻璃体内视网膜淋巴瘤累及脊髓，替拉鲁替尼治疗暂时完全缓解。
Intern Med. 2023 Feb 1;62(3):459-463. doi: 10.2169/internalmedicine.9591-22. Epub 2022 Jul 5.
2
Primary vitreoretinal lymphoma: a diagnostic and management challenge.原发性玻璃体视网膜淋巴瘤：诊断和治疗的挑战。
Blood. 2021 Oct 28;138(17):1519-1534. doi: 10.1182/blood.2020008235.
3
Diagnosis and management of vitreoretinal lymphoma: present and future treatment perspectives.玻璃体内视网膜淋巴瘤的诊断与治疗：现状与未来治疗展望。
Jpn J Ophthalmol. 2023 Jul;67(4):363-381. doi: 10.1007/s10384-023-00997-6. Epub 2023 May 20.
4
Primary vitreoretinal lymphoma.原发性玻璃体视网膜淋巴瘤
Indian J Ophthalmol. 2015 Mar;63(3):180-6. doi: 10.4103/0301-4738.156903.
5
Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.系统大剂量甲氨蝶呤和联合治疗在眼内淋巴瘤治疗中的作用：1990-2018 年单中心经验。
Am J Hematol. 2019 Mar;94(3):291-298. doi: 10.1002/ajh.25350. Epub 2018 Dec 5.
6
Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.原发性玻璃体视网膜淋巴瘤患者眼部表现及预防性治疗与中枢神经系统受累发生之间的关联
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):687-93. doi: 10.1007/s00417-014-2584-8. Epub 2014 Feb 19.
7
Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium.原发性眼玻璃体视网膜淋巴瘤：国际原发性中枢神经系统淋巴瘤协作组研讨会报告。
Oncologist. 2011;16(11):1589-99. doi: 10.1634/theoncologist.2011-0210. Epub 2011 Nov 1.
8
[Diagnostics and treatment of primary vitreoretinal lymphoma].[原发性玻璃体视网膜淋巴瘤的诊断与治疗]
Ophthalmologe. 2015 Mar;112(3):223-30. doi: 10.1007/s00347-014-3204-z.
9
Primary Vitreoretinal Lymphoma -- A Review.原发性玻璃体视网膜淋巴瘤——综述
Asia Pac J Ophthalmol (Phila). 2017 May-Jun;6(3):283-289. doi: 10.22608/APO.2017150.
10
Long-lasting CRs after ibrutinib monotherapy for relapse or refractory primary CNS lymphoma (PCNSL) and primary vitreoretinal lymphoma (PVRL): Long-term results of the iLOC study by the Lymphoma Study Association (LYSA) and the French Oculo-Cerebral Lymphoma (LOC) Network (clinical trial number: NCT02542514).伊布替尼单药治疗复发或难治性原发性中枢神经系统淋巴瘤（PCNSL）和原发性玻璃体视网膜淋巴瘤（PVRL）后的持久完全缓解：淋巴瘤研究协会（LYSA）和法国眼脑淋巴瘤（LOC）网络进行的iLOC研究的长期结果（临床试验编号：NCT02542514）
Eur J Cancer. 2023 Aug;189:112909. doi: 10.1016/j.ejca.2023.04.025. Epub 2023 Jun 8.

引用本文的文献

1
Bruton's tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review.布鲁顿酪氨酸激酶抑制剂在原发性中枢神经系统淋巴瘤治疗中的应用：一篇综述。
Front Oncol. 2022 Nov 17;12:1034668. doi: 10.3389/fonc.2022.1034668. eCollection 2022.

本文引用的文献

1
Tumor cell-derived IL-10 promotes cell-autonomous growth and immune escape in diffuse large B-cell lymphoma.肿瘤细胞衍生的白细胞介素 10 促进弥漫性大 B 细胞淋巴瘤的细胞自主生长和免疫逃逸。
Oncoimmunology. 2021 Nov 22;10(1):2003533. doi: 10.1080/2162402X.2021.2003533. eCollection 2021.
2
Cytologic and Molecular Diagnostics for Vitreoretinal Lymphoma: Current Approaches and Emerging Single-Cell Analyses.玻璃体视网膜淋巴瘤的细胞学和分子诊断：当前方法与新兴的单细胞分析
Front Mol Biosci. 2021 Jan 11;7:611017. doi: 10.3389/fmolb.2020.611017. eCollection 2020.
3
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
替拉鲁替尼（第二代布鲁顿酪氨酸激酶抑制剂）治疗复发/难治性原发性中枢神经系统淋巴瘤的 I/II 期研究。
Neuro Oncol. 2021 Jan 30;23(1):122-133. doi: 10.1093/neuonc/noaa145.
4
Gene expression profiling of primary vitreoretinal lymphoma.原发性玻璃体视网膜淋巴瘤的基因表达谱分析。
Cancer Sci. 2020 Apr;111(4):1417-1421. doi: 10.1111/cas.14347. Epub 2020 Mar 12.
5
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.替拉鲁替尼和其他布鲁顿酪氨酸激酶不可逆抑制剂的生化特征揭示了靶内和靶外抑制的差异。
Biochim Biophys Acta Gen Subj. 2020 Apr;1864(4):129531. doi: 10.1016/j.bbagen.2020.129531. Epub 2020 Jan 15.
6
Combined intravitreal methotrexate and immunochemotherapy followed by reduced-dose whole-brain radiotherapy for newly diagnosed B-cell primary intraocular lymphoma.玻璃体腔注射甲氨蝶呤联合免疫化疗，随后进行低剂量全脑放疗用于新诊断的B细胞原发性眼内淋巴瘤。
Br J Haematol. 2017 Oct;179(2):246-255. doi: 10.1111/bjh.14848. Epub 2017 Jul 12.
7
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial.甲氨蝶呤、阿糖胞苷、噻替派和利妥昔单抗联合化疗免疫疗法（MATRix方案）用于原发性中枢神经系统淋巴瘤患者：国际结外淋巴瘤研究组-32（IELSG32）2期试验首次随机分组结果
Lancet Haematol. 2016 May;3(5):e217-27. doi: 10.1016/S2352-3026(16)00036-3. Epub 2016 Apr 6.
8
Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227.甲氨蝶呤、利妥昔单抗和替莫唑胺诱导化疗，继以全脑放疗和放疗后替莫唑胺治疗原发性中枢神经系统淋巴瘤的I期和II期研究：NRG肿瘤学RTOG 0227
J Clin Oncol. 2016 May 10;34(14):1620-5. doi: 10.1200/JCO.2015.64.8634. Epub 2016 Mar 28.
9
High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.玻璃体内 B 细胞淋巴瘤中 MYD88 突变的高频：提高玻璃体液抽吸物诊断率的有价值工具。
Blood. 2015 Jul 2;126(1):76-9. doi: 10.1182/blood-2015-01-620518. Epub 2015 Apr 21.
10
Clinical features and diagnostic significance of the intraocular fluid of 217 patients with intraocular lymphoma.217 例眼内淋巴瘤患者眼内液的临床特征和诊断意义。
Jpn J Ophthalmol. 2012 Jul;56(4):383-9. doi: 10.1007/s10384-012-0150-7. Epub 2012 Jun 5.